Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.
The aim of the study was to evaluate the expression of TMEM67 in urothelial carcinoma of the bladder (UCB) tissues and to determine the potential relevance between the expression of TMEM67 and prognosis of UCB.



In this study, the expression of TMEM67 mRNA was performed by quantitative real-time PCR in 80 UCB and 54 noncancerous tissues. The expression of TMEM67 protein was identified by immunohistochemistry and western blotting. Chi-square test was conducted to verify the relevance between the expression of TMEM67 and clinical parameters. Kaplan-Meier survival analysis was demonstrated between high or low expression level of TMEM67 mRNA and recurrence-free survival probability. Cox regression analysis was conducted to evaluate the relevance between the expression of TMEM67 and the prognosis in UCB.



Low expression of TMEM67 mRNA and protein was detected in most of UCB tissues using quantitative real-time polymerase chain reaction and western blotting, compared with noncancerous tissues. Low expressions of TMEM67 were associated with TNM stage, grade, and lymph node metastasis (P<0.05). Kaplan-Meier analysis showed that the low expression of TMEM67 mRNA had significantly shorter recurrence-free survival probability (P = 0.018). Cox regression analysis confirmed that low expression of TMEM67 mRNA predicted poor prognosis of patients with UCB (HR = 2.950, P = 0.029, 95% CI: 1.116-7.796).



TMEM67 expression is low in UCB tissues, and the TMEM67 low expression predicted poor prognosis of patients with UCB.
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
E
E
Du
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
Changwen
C
Zhang
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
Zhenbang
Z
Qin
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
Kuo
K
Yang
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
Changying
C
Li
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China.
Aixiang
A
Wang
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China. Electronic address: zhangzhihongtianj@163.com.
Zhihong
Z
Zhang
Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin, China. Electronic address: yongxutj@126.com.
Yong
Y
Xu
D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000378:metabolism / Q000556:secondary*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
D014408:Biomarkers, Tumor; D008565:Membrane Proteins; C468846:TMEM67 protein, human
Gene expression; Prognosis; Urothelial carcinoma of the bladder